Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    88,496.37
    +992.64 (+1.13%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.64%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know

Zacks Equity Research
·2 min read

Viatris (VTRS) closed at $14.36 in the latest trading session, marking a -1.17% move from the prior day. This move lagged the S&P 500's daily gain of 0.28%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 0.16%.

Prior to today's trading, shares of the generic drugmaker had gained 6.6% over the past month. This has outpaced the Medical sector's loss of 9.62% and the S&P 500's loss of 5.39% in that time.

Viatris will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.82, down 12.77% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.31 billion, up 19.03% from the year-ago period.

Any recent changes to analyst estimates for Viatris should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

ADVERTISEMENT

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Viatris is currently sporting a Zacks Rank of #4 (Sell).

Digging into valuation, Viatris currently has a Forward P/E ratio of 3.94. For comparison, its industry has an average Forward P/E of 22.85, which means Viatris is trading at a discount to the group.

The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 197, which puts it in the bottom 23% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Viatris Inc. (VTRS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.